Test ID: GD65S
Glutamic Acid Decarboxylase (GAD65) Antibody Assay, Serum
Secondary ID 
A test code used for billing and in test definitions created prior to November 2011
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Useful For Suggests clinical disorders or settings where the test may be helpful
Assessing susceptibility to autoimmune (type 1, insulin-dependent) diabetes mellitus and related endocrine disorders (eg, thyroiditis and pernicious anemia). Titers generally < or = 0.02 nmol/L. A second islet cell antibody, IA-2, is more predictive for development of type 1 diabetes, but less frequent than GAD65 Ab amongst diabetic patients. Insulin autoantibodies also serve as a marker of susceptibility to type 1 diabetes.
Distinguishing between patients with type 1 and type 2 diabetes. Assays for IA-2, insulin, gastric parietal cell, thyroglobulin, and thyroid peroxidase antibodies, complement GAD65 antibody in this context. Titers generally < or = 0.02 nmol/L.
Confirming a diagnosis of stiff-man syndrome, autoimmune encephalitis, cerebellitis, brain stem encephalitis, myelitis. Titers generally > or = 0.03 nmol/L.
Confirming susceptibility to organ-specific neurological disorders (eg, myasthenia gravis, Lambert-Eaton syndrome). Titers generally < or = 0.02 nmol/L.
Method Name A short description of the method used to perform the test
Radioimmunoassay (RIA)
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Aliases Lists additional common names for a test, as an aid in searching
Anti-GAD Antibodies
Anti-Glutamic Acid Decarboxylase Ab
Beta Cell Antibody
GAD65 Antibody Assay
Pancreatic Islet Cell Ab
Stiffman Syndrome
Glutamate Decarboxylase Antibodies (GAD65)
External
link
PDF
document
Excel
document
Word
document